NCT03611010View on ClinicalTrials.gov

Dose-ranging Efficacy and Pharmacokinetics Study of Intravenous Atorvastatin in Hypercholesterolemic Patients

PHASE2CompletedINTERVENTIONAL
Enrollment

40

Participants

Timeline

Start Date

August 7, 2018

Primary Completion Date

February 17, 2020

Study Completion Date

February 24, 2020

Conditions
HypercholesterolemiaDyslipidemias
Interventions
DRUG

Atorvastatin injection

statin (i.e., 3-hydroxy-3-methylglutaryl-coenzyme A (HMG-CoA) reductase inhibitor) for injection

Trial Locations (1)

07094

Frontage Clinical Services, Secaucus

Sponsors
All Listed Sponsors
lead

Cumberland Pharmaceuticals

INDUSTRY